 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | GeloMyrtol (ELOM-080) / Nadurel Pharma
Journal: Phytomedicine ELOM-080 in Acute Viral Rhinosinusitis: A Randomized, Placebo-Controlled, Blinded Clinical Trial. (Pubmed Central) - Oct 13, 2022
ELOM-080 improves the burden of AVRS significantly in comparison to placebo, remission of symptoms occurred 3 days earlier. The results confirm the efficacy and safety of ELOM-080 for treatment of AVRS.
- | GeloMyrtol (ELOM-080) / Nadurel Pharma
Journal: Efficacy and Safety of ELOM-080 as Add-On Therapy in COVID-19 Patients with Acute Respiratory Insufficiency: Exploratory Data from the Prospective Placebo-Controlled COVARI Trial. (Pubmed Central) - May 26, 2022
P2
The results confirm the efficacy and safety of ELOM-080 for treatment of AVRS. These exploratory data suggest the potential for ELOM-080 to improve respiratory status during and after hospitalisation in patients with COVID-19.
- || GeloMyrtol (ELOM-080) / Nadurel Pharma
PK/PD data, Journal: Food Interactions Observed in a Pharmacokinetic Investigation Comparing Two Marketed Cold Preparations (BNO1016 and ELOM-080) after Administration to Beagle Dogs - A Pilot Study. (Pubmed Central) - May 7, 2022
Furthermore, lag times of some analytes, up to 3 - 4 h, and corresponding time to reach maximum concentration values, up to 6 - 8 h, occurred. In contrast to BNO 1016, these findings suggest that, as with other enteric-coated formulations, there may also be a significant risk for food effects with ELOM-080 in humans.
- | GeloMyrtol (ELOM-080) / Nadurel Pharma
Journal: Celecoxib and Myrtol: A Novel Therapy for Recurrent Appendiceal Mucinous Neoplasms With Extensive Peritoneal Dissemination. (Pubmed Central) - Feb 15, 2022
In contrast to BNO 1016, these findings suggest that, as with other enteric-coated formulations, there may also be a significant risk for food effects with ELOM-080 in humans. Our feasibility study suggests that a regimen of Celecoxib-Myrtol is well tolerated and may prolong PFS and OS in patients with recurrent AMNs with peritoneal spread.
- |||| GeloMyrtol (ELOM-080) / Nadurel Pharma
New P2 trial: A clinical trial to assess the efficacy and safety of PB432 in COVID-19 positive inpatients with acute respiratory problems (EUDRACT) - Dec 29, 2020
P2, N=150, Ongoing, Sponsor: G. Pohl-Boskamp GmbH & Co. KG